

Role of Intracellular Calcium in Clotrimazole-Induced Alteration of Cell Cycle Inhibitors, p53 and p27, in HT29 Human Colon Adenocarcinoma Cells

Dinesh THAPA, Jun Bum KWON, and Jung-Ae KIM*

College of Pharmacy, Yeungnam University, Gyeongsan 712-749, South Korea

(Received January 7, 2008; Accepted March 10, 2008)

Abstract – Clotrimazole (CLT), a potent antifungal drug, is known to inhibit tumor cell proliferation. In the present study, we examined the role of intracellular Ca^{2+} in CLT-induced cell cycle arrest of colon adenocarcinoma HT29 cells. CLT inhibited growth of HT29 cells in a concentration-dependent manner, which was associated with inhibition of cell cycle progression at the G(1)-S phase transition and an increase in the expression of cell cycle inhibitor proteins p27 and p53. CLT also suppressed the Ca^{2+} overload by A23187, a calcium ionophore, suggesting its role in modulation of intracellular Ca^{2+} concentration in HT29 cells. The simultaneous application of CLT and A23187 with addition of $CaCl_2$ (1 mM) to the medium significantly reversed CLT-induced p27 and p53 protein level increase and growth suppression. Our results suggest that CLT induces cell cycle arrest of colon adenocarcinoma HT29 cells via induction of p27 and p53, which may, at least in part, be mediated by alteration of intracellular Ca^{2+} level.

Key words □ Intracellular Ca^{2+} , Cell cycle arrest, Clotrimazole, p27, p53

INTRODUCTION

It is widely accepted that the Ca^{2+} is a ubiquitous intracellular signal responsible for controlling numerous cellular processes such as cell growth and cell cycle progression (Cheng *et al.*, 1996, Berridge *et al.*, 2000, Kahl and Means, 2003). The alteration of intracellular Ca^{2+} concentration controls cellular processes such as proliferation, fertilization and development. However, when exceeding its normal spatial and temporal boundaries, Ca^{2+} can result in cell death through both necrosis and apoptosis (Berridge *et al.*, 2000). Therefore, intracellular Ca^{2+} concentration is absolutely required not only for mitosis and cell growth progression through G1 but also for survival (Hazelton *et al.*, 1979, Kahl and Means, 2003).

Clotrimazole (CLT), an antifungal imidazole derivative that has been in clinical use for more than 20 years, inhibits proliferation of variety of human cancer cells originated from breast (Ouaïd-Ahidouch *et al.*, 2004), pancreas (Jager *et al.*, 2004) and prostate (Parihar *et al.*, 2003) *in vitro*. More recently, it has been shown that growth inhibi-

tory effect of CLT results from the cell cycle arrest at G1 by reducing the expression of G1 cyclin (Aktas *et al.*, 1998). In an *in vivo* mouse model, CLT is also known to exert inhibitory effect on tumor growth (Khalid *et al.*, 2005; Takahashi *et al.*, 1998) and metastasis (Benzaquen *et al.*, 1995). Unlike the antimycotic effect that is mediated through inhibition of sterol-1,4-demethylase, a cytochrome P-450-dependent enzyme (Yoshida and Aoyama, 1987), anti-cancer effect of CLT is suggested to be mediated by a novel mechanism involving Ca^{2+} store-mediated inhibition of translation initiation in human cancer cells (Benzaquen *et al.*, 1995). Specifically, CLT induces the release of Ca^{2+} from endoplasmic reticulum intracellular stores and blocks the influx of extracellular Ca^{2+} through Ca^{2+} store-regulated Ca^{2+} channels. The sustained depletion of intracellular Ca^{2+} stores activates RNA-dependent protein kinase R, resulting in phosphorylation of eukaryotic translation initiation factor (eIF2 α) at serine 51 and its concomitant inactivation. Inactivation of eIF2 α inhibits the formation of ternary complex between Met-tRNA, eIF2 α , and GTP, a rate-limiting step in translation initiation. This results in an abrogation of synthesis of growth promoting proteins such as cyclin D, E, and A at the level of translation initiation, leading to growth arrest in early G1 (Aktas *et al.*, 1998, Apati *et al.*, 2003). On the other hand, a group of the pro-

*Corresponding author

Tel: +82-53-810-2816, Fax: +82-53-810-3871

E-mail: jakim@yu.ac.kr

teins that acts on fundamental regulator of the cell cycle transitions is the cyclin-dependent kinases (CDKs) (Morgan, 1995). The family of p21/p27 protein binds CDK complexes to inhibit kinase activity, thereby playing a negative role in cell cycle progression. Furthermore, p53 protein also inhibits cell cycle progression (Kastan *et al.*, 1991). Although CLT is known to inhibit cell cycle progression, its action on cell cycle inhibitors has not been elucidated.

Therefore the purpose of this study was to examine the role of intracellular Ca^{2+} in growth and cell cycle progression via regulation of cell cycle related proteins in HT29 human colon adenocarcinoma cells. In the present study, we examined the expression level of cell cycle inhibitors such as p53 and p27 are associated with alterations in intracellular Ca^{2+} level.

MATERIALS AND METHODS

Chemicals

The liquid RPMI1640 medium, fetal bovine serum and antibiotics (penicillin and streptomycin mixture) were purchased from GIBCO (Grand Island, NY, USA). A23187, trypsin-EDTA solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), sodium pyruvate, propidium iodide, ribonuclease A, bovine serum albumin (BSA), dimethyl sulfoxide (DMSO), protease inhibitor cocktail, sodium dodecyl sulfate (SDS), nitroblue tetrazolium (NBT) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Fura-2 AM was purchased from Molecular Probes. CLT was supplied from Korea United Pharm. Inc. (Seoul, Korea).

Cell line and cell culture

The HT29 human colon cancer cell line was purchased from American Type Culture Collection (Rockville, MA, USA), and were grown in RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 200 IU/ml penicillin/200 μ g/ml streptomycin and 2 mmol/L glutamine, at 37°C under 5% CO_2 /95% air. During propagation, the culture medium was changed every other day, and subcultured weekly using Dulbecco's PBS containing 0.25 % trypsin and 1% EDTA.

Cell viability assay (MTT Assay)

Cell viability was measured by the 3-[4, 5- dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay, which is based on the conversion of MTT into an insoluble

purple formazan crystals by mitochondrial dehydrogenases. Cells were plated at a density of 2×10^4 cells/100 μ l medium in a 96-well plate and treated with CLT for given time. The medium was incubated with 10 μ l of 5 mg/ml of MTT solution for 4 hr at 37°C. Culture medium was then aspirated, and formazan was instantly dissolved by the addition of 200 μ l of DMSO. Absorbance was measured at 540 nm using a microplate reader (Molecular Devices, Versa MAX Sunnyvale, CA, USA). The cell viability was expressed as a percent of the control culture.

Cell cycle and apoptosis analysis

For flow cytometry analysis, cells were starved for 24 h and then released into complete medium with different concentrations of CLT for 24 h. The cells were collected and washed twice with a PBS buffer (pH 7.4). After fixing in 80% ethanol for 30 min, cells were then washed twice, and resuspended in a PBS buffer (pH 7.4) containing 0.1% Triton X-100, 100 μ g/ml PI and 50 μ g/ml ribonuclease A for DNA staining. Cells were then analyzed by a FACScalibur (Becton Dickson, USA). At least 20,000 events per sample were evaluated. All histograms were analyzed using Cell Quest (Becton Dickson, USA) to determine the percentage of cells in the G1, S and G2/M stages of the cell cycle. The percentage of nuclei with hypodiploid content indicative of apoptosis was also analyzed (Hockenbery *et al.*, 1990).

Cellular extraction and Western Blot analysis

Nuclear and total protein extractions were carried out according to previous procedure (Li *et al.*, 2006) with some modifications. Briefly, cells were scraped in 1 ml aliquot of ice-cold PBS, collected by centrifugation (3500 rpm for 5 min, 4°C), and the cell pellet was washed in a 1 ml aliquot of buffer A (10 mM Tris, pH 7.9; 1.5 mM $MgCl_2$; 10 mM KCl). The cells were then resuspended in five volumes of ice-cold modified buffer A (10 mM Tris, pH 7.9; 1.5 mM $MgCl_2$; 10% NP40; 1 mM DTT and 0.5 mM PMSF) containing 1x protease inhibitor cocktail. The resuspended cells were homogenized and left on ice (4°C) for 15 min. The homogenates were centrifuged at 12000 rpm for 10 min. Supernatant (cytoplasmic fraction) was transferred to a fresh tube and stored at -70°C. To lyse the cell pellet containing nuclear fraction, a 50 μ l aliquot of buffer C (Tris 10 mM, pH 7.9, 1.5 mM $MgCl_2$, 25% Glycerol, 5 mM NaCl, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 0.5 mM Na_3VO_3 , and 1x protease inhibitor cocktail,

was added. The pellets were vortexed for 1 min, left on ice (4°C) for 40 min, and centrifuged for 10 min (4°C, 12000 rpm) to collect the supernatant (nuclear fraction).

The soluble protein concentrations in cytoplasmic or nuclear lysates were determined by BCA™ protein assay kit (Pierce, Rockford, USA). Western blot analysis was carried out by separating equal amounts of proteins (20 µg) on SDS-PAGE and transferring to a Hybond ECL nitrocellulose membrane (Amersham Life Science, Buckinghamshire, UK) at 200 mA for an hour. Subsequently, membranes were blocked for 1 h at room temperature with 5% (w/v) skimmed milk in Tris-buffered saline containing 0.05% Tween 20 (TBS-T). Membranes were then incubated overnight at 4°C with the mouse monoclonal antibody against human p53 (Santa Cruz, CA), rabbit polyclonal antibody against human p27 (Santa Cruz, CA), and anti-human actin antibody (Santa Cruz, CA). After incubation with a corresponding horseradish peroxidase-conjugated anti-IgG antibody (all from Santa Cruz, CA), immunoreactive proteins were visualized with ECL kit (Amersham Life Science, Buckinghamshire, UK). For quantitative analysis, bands were detected by densitometry, using an Image Analyzing System (UVP, upland, USA).

Intracellular Ca²⁺ measurement

Briefly, HT29 cells were seeded at the density of 2×10^5 cells/cm² in 6-well plate (Nunc Denmark). After 24 hours of seeding, the monolayer was washed with PBS and added serum free RPMI 1640 media. Fura-2 AM at a final concentration of 3 µM was added to the monolayer, and was incubated for 50 min at 37°C. After being washed with Locke's solution containing 250 µM sulfapyrazone for 3 times, cells were further incubated for 30 min in serum free media. Fura-2 loaded cells were then incubated with CLT for 10 min at 37°C. These experiments were performed in the presence of 1 mM CaCl₂, or EGTA alone. Finally, the monolayers were stimulated by the addition of Ca²⁺ ionophore A23187 at a final concentration of 1 µM. Fura-2 fluorescence was measured using a fluorescence detector, FLUOstar optima (BMG Labtech, Germany) with an excitation wavelength at 340/380 nm and the emission wavelength at 510 nm.

Data analysis

The data were expressed as the mean ± standard error of the mean (SEM) and analyzed using one-way analysis of variance (ANOVA) and Student-Newman-Keul's test for




Fig. 1. Effects of CLT on the viability of HT29 human colon cancer cells. Cells treated with CLT for 48 h were analyzed for the viability by MTT assay. The data represent the mean values of four replications with bars indicating S.E.M.

individual comparisons. P values less than 0.05 were considered statistically significant.

RESULTS

CLT inhibits cell cycle progression and induces apoptosis in HT29 human colon cancer cells

It has been known that CLT inhibits cell proliferation in




Fig. 2. Effect of CLT on cell cycle arrest in HT29 cells. Cells were starved serum (1% FBS) for 24 hr, and then, stimulated with 10% FBS in the absence or presence of CLT. After 24 hr, the cells were collected and then stained with propidium iodide for the cell cycle analysis using flow cytometry.

Table I. CLT-induced cell cycle arrest in G₁ phase.

CLT (μM)	A ₀ (%)	G ₁ (%)	S (%)	G ₂ /M (%)
0	1.14±0.04	63.7±0.58	11.49±0.27	23.53±0.35
1	1.25±0.09	62.5±0.42	11.95±0.09	24.03±0.39
25	2.25±0.08*	81.0±0.10*	5.71±0.17*	10.81±0.28*
50	39.44±1.93*	48.8±1.17*	7.35±0.45*	6.35±0.30*

HT29 cells were synchronized in the medium without FBS for 24 hr and then released into complete medium containing 0.1% DMSO or different concentrations of CLT. After incubation for 24 h, the cells were harvested, stained with propidium iodide, and analyzed for DNA contents by using flow cytometry. A₀ represents the percentage of nuclei with hypodiploid content indicative of apoptosis. **P*<0.05 compared to vehicle-treated control.

various cancer cell lines. However, the effect of CLT in colon cancer has not been reported. We first examined the effect of CLT on the viability of HT29 human colon cancer cells. As shown in Fig. 1, treatment with CLT for 48 h decreased cell viability in a dose-dependent manner with an IC₅₀ of 25 μM . To further examine the effect of CLT on the cell cycle progression, serum starved cells were then treated with increasing concentrations of CLT along with complete medium. As shown in Fig. 2 and Table I, the population of cells in the S phase was 11.49±0.27% in the presence of 10% serum. CLT (25 μM) decreased the S phase population to 5.71±0.17%, while increasing the G₁ phase population from 63.7±0.58% to 81.0±0.10%. Higher concentration of CLT (50 μM) decreased the population of cells in the S phase from 11.49±0.27% to 7.35±0.45% and G₁ phase from 63.7±0.58% to 48.8±1.17%, but significantly increased cells in sub-G₁ phase from 1.14±0.04% to 39.44±1.93%.

Effects of CLT on the cell cycle-related proteins

In order to understand the exact mechanism of CLT-induced cell cycle arrest in HT29 cells, we examined the effect of CLT on the level of cell cycle inhibitor p27 and p53 proteins. As depicted in Fig. 3, CLT (25 μM) significantly increased the expression level of p27 time-dependently up to 24 h, thereafter, decreased at 48 hr. In addition, CLT increased the expression of p53 slightly up to 24 h, and tremendously at 48 h.

Intracellular Ca²⁺ involvement in the CLT-induced cell cycle arrest

Since CLT is known to modulate intracellular Ca²⁺ concentration and Ca²⁺-dependent processes, we measured CLT-induced changes in the intracellular Ca²⁺ level in HT29 cells. The A23187 (1 μM), a known calcium iono-




Fig. 3. Effects of CLT on the expression of p27 (A) and p53 (B) in HT29 cells. Cells were treated with CLT (25 μM) at different time points. The control cells received an equal volume of DMSO. In each experiment, nuclear proteins were isolated, and the level of p27 and p53 proteins was detected with anti-human p27 and p53 antibodies, respectively. Equal loading was confirmed by measuring actin proteins. Experiments were repeated 3 times and the bar graph represents the band intensity quantitated by densitometry. **P*<0.05, compared to vehicle (DMSO)-treated controls.

phore, was used to induce the basal Ca²⁺ level in the cells. As shown in Fig. 4, the incubation of HT29 cells with A23187 progressively increased the Ca²⁺ level as calculated by a Ca²⁺-sensitive fluorescence dye, Fura-2. CLT concentration-dependently reduced A23187-induced intracellular Ca²⁺ increase up to a control level.

To explore the involvement of intracellular Ca²⁺ in CLT-




Fig. 4. The effect of CLT on A23187-induced intracellular Ca^{2+} level. The Fura-2-loaded cells were treated with CLT in serum-free RPMI 1640 containing CaCl_2 (1 mM). A23187 (1 μM) was added to the medium in the absence or presence of CLT for 10 min. Intracellular Ca^{2+} level was measured by using a fluorescence-detecting microplate reader (FLUOstar Optima, BMG Labtech, Germany) with an excitation wavelength alternating every 30 sec from 340 to 380 nm and the emission wavelength was set at 510 nm. One representative graph of four independent experiments is shown in (A). The bar graph (B) represents the mean \pm SEM at 10, 20 and 30 min of A23187 incubation of four independent experiments. The letters C, D, E, and F represent vehicle-treated control in the presence of EGTA, A23187 alone, A23187 with CLT (5 μM), and A23187 with CLT (10 μM), respectively.

induced cell cycle arrest in HT29 cells, we then examined that co-treatment with A23187 and CLT alters CLT-induced expression of cell cycle inhibitors. As shown in Fig 5, CLT-induced increase in p27 and p53 was suppressed by co-treatment with A23187 (1 μM). Interestingly, addition of 1 mM of CaCl_2 to the medium significantly enhanced the effect of A23187 on the CLT-induced increase in p27 and p53.

Similar to the preventing effect of A23187 on CLT-induced changes of cell cycle inhibitors, co-treatment of cells with A23187 in the presence of 1 mM of CaCl_2 reversed the CLT-induced inhibition of cell growth (Fig. 6).




Fig. 5. Effects of calcium ionophore A23187 on CLT-activated p27 and p53. HT29 cells were treated with A23187 (1 μM) and CLT (25 μM) for 12 h concomitantly. Nuclear proteins were isolated, and p27 and p53 proteins were determined by western blot. Equal loading was confirmed by probing with antibodies against actin. Experiments were repeated 3 times and the bar graph represents the band intensity quantitated by densitometry. * $P < 0.05$, compared to vehicle (DMSO)-treated controls. # $P < 0.05$, compared to CLT-treated group.

DISCUSSION

CLT has been suggested as a potential agent for the treatment of cancer. It has been reported that CLT inhibits cell proliferation, and antiproliferative effect of CLT in a number of cancer cells has been suggested by blocking the cell cycle via interfering Ca^{2+} homeostasis. In the present study, we report that CLT inhibited serum-induced growth by halting cell cycle progression at the G(1)-S




Fig. 6. Preventive Effects of A23187 on CLT-inhibited cell proliferation. Cells were starved serum (1% FBS) for 24 hr, and then, stimulated with 10% FBS in the absence or presence of CLT and A23187. CaCl₂ (1 mM) was added to the medium as it was needed. After 24 hr, the cells analyzed for the viable cell number by MTT assay. The data represent the mean values of four replications with bars indicating S.E.M. * $P < 0.05$, compared to serum-starved controls. # $P < 0.05$, compared to 10% FBS-stimulated group. \$ $P < 0.05$, compared to 10% FBS-stimulation and CLT-treated group.

phase transition through induction of cell cycle inhibitors, p27 and p53 in HT29 colon adenocarcinoma cells.

The cell cycle regulatory pathway is one of the useful targets for drug and gene therapy of cancers (Hunter and Pines, 1994). Cell cycle progression is regulated by sequential formation and activation of a series of cyclin-CDK complexes (Toyoshima and Hunter 1994; Ohtsubo and Roberts, 1993). CLT has been shown to block the cell cycle specifically in G1 by reducing synthesis and expression of G1 cyclins, thereby inhibiting the associated CDK activity required for progression into S phase (Aktas *et al.*, 1998). Similar to that, our results in HT29 cells showed that the growth inhibition by CLT was associated with the arrest of cells in G1 phase. Furthermore, we showed that CLT upregulated cell cycle inhibitors p27 and p53. p27 is one of the important members of *cip/kip* family, which are responsible for halting cell cycle in G1 phase, by binding to, and inactivating, cyclin-CDK complexes. p53, usually triggered by DNA damage, activates p21 and thus plays a significant role to halt cell cycle progression in G1 phase. In addition to cell cycle arrest, high amount of p53 expression induces apoptotic cell death. In the present study, low level of p53 expression was kept at low and short expo-

sure to CLT, which corresponds to cell cycle arrest. In contrast, the p53 level was extensively increased in the cells exposed to high concentration of CLT for longer time period, which corresponded to the significantly increased apoptotic events.

Calcium has long been recognized as an important component in regulating cell growth and cell cycle progression. The alteration of intracellular Ca²⁺ concentration control cellular processes such as fertilization, proliferation and development. It has been reported that anticancer effects of CLT is mediated through depletion of intracellular Ca²⁺ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the (Aktas *et al.*, 1998). Benzaquen *et al.* (1995) also reported that CLT depletes the intracellular Ca²⁺ stores and prevents the rise in cytosolic Ca²⁺ that normally follows mitogenic stimulation. This was in accordance to our finding that CLT depleted intracellular Ca²⁺ induced by calcium ionophore, A23187. Furthermore, in the search of the action mechanism of CLT that lead to cell cycle arrest in HT29 cells, we showed that our results suggest a link between the Ca²⁺ signal and cell cycle inhibitors. The increased intracellular Ca²⁺ by A23187 reversed the effect of CLT in induction of cell cycle inhibitors. In addition, the recovery effect was more obvious when addition of CaCl₂ to the A23187 and CLT co-treated cells. In correlation to the results of intracellular Ca²⁺ and cell cycle related proteins, the antiproliferative effect of CLT was recovered by A23187, suggesting that intracellular Ca²⁺ regulates cell cycle progression, and that the action of CLT may at least in part be mediated by targeting intracellular Ca²⁺ signal for induction of cell cycle related proteins.

In summary, CLT inhibited cell cycle progression in HT29 colon cancer cells by up-regulating the important cell cycle inhibitor proteins, p27 and p53. Importantly, our findings provide a novel crosstalk pathway between intracellular Ca²⁺ and the Ca²⁺ signaling-mediated regulation of the cell cycle related proteins in colon cancer cells. These findings suggest an action mechanism of CLT in HT29 cells and the use of selective intracellular Ca²⁺ modulators like CLT as a valid chemotherapeutic agent in colon cancer.

ACKNOWLEDGMENTS

This work was supported by a grant No. RTI04-01-04 from the Regional Technology Innovation Program of the

Ministry of Commerce, Industry, and Energy (MOCIE).

REFERENCES

- Aktas, H., Flückiger, R., Acosta, J.A., Savage, J.M., Palakurthi, S.S. and Halperin, J.A. (1998). Depletion of intracellular Ca^{2+} stores, phosphorylation of eIF2 α , and sustained inhibition of translation initiation mediate the anticancer effects of CLT. *Proc Natl Acad Sci U S A*. **95**(14), 8280-8285.
- Apati, A., Janossy, J., Brozik, A., Bauer, P.I. and Magocsi, M. (2003). Calcium induces cell survival and proliferation through the activation of the MAPK pathway in a human hormone-dependent leukemia cell line, TF-1. *J Biol Chem*. **278**(11), 9235-9243.
- Benzaquen, L.R., Brugnara, C., Byers, H.R., Gatten-Celli, S. and Halperin, J.A. (1995). CLT inhibits cell proliferation in vitro and in vivo. *Nat Med*. **1**(6), 534-540.
- Berridge, M.J. (1995). Calcium signalling and cell proliferation. *BioEssays* **17**, 491-500.
- Berridge, M.J., Lipp, P. and Bootman, M.D. (2000). The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol*. **1**(1), 11-21.
- Brugnara, C., de Franceschi, L. and Alper, S.L. (1993). Inhibition of Ca^{2+} -dependent K^+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. *J. Clin. Invest.* **92**, 520-526.
- Buolamwini, J.K. (2000). Cell cycle molecular targets in novel anticancer drug discovery. *Curr Pharm Des.* **6**(4), 379-392.
- Cheng, G., Liu, B.F., Yu, Y., Diglio, C. and Kuo, T.H. (1996). The exit from G(0) into the cell cycle requires and is controlled by sarco(endo)plasmic reticulum Ca^{2+} pump. *Arch Biochem Biophys*. **329**(1), 65-72.
- Hazelton, B., Mitchell, B. and Tupper, J. (1979). Calcium, magnesium, and growth control in the WI-38 human fibroblast cell. *J Cell Biol*. **83**(2 Pt 1), 487-498.
- Hockenbery, D., Nuñez, G., Millman, C., Schreiber, R.D. and Korsmeyer, S.J. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature*. **348**(6299), 334-336.
- Hunter, T., and Pines, J. (1994). Cyclins and cancer. II: Cyclin D and CDKCDK inhibitors come of age. *Cell* **79**, 573-582.
- Jager, H., Dreker, T., Buck, A., Giehl, K., Gress, T. and Grissmer, S. (2004). Blockage of intermediate-conductance Ca^{2+} -activated K^+ channels inhibit human pancreatic cancer cell growth in vitro. *Mol Pharmacol*. **65**(3), 630-638.
- Kahl, C.R. and Means, A.R. (2003). Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. *Endocr Rev*. **24**(6), 719-736.
- Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R.W. (1991). Participation of p53 protein in the cellular response to DNA damage. *Cancer Res*. **51**(23 Pt 1), 6304-6311.
- Khalid, M.H., Tokunaga, Y., Caputy, A.J. and Walters, E. (2005). Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of CLT. *J Neurosurg*. **103**(1), 79-86.
- Li, M., Lee, T.W., Yim, A.P., Mok, T.S. and Chen, G.G. (2006). Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. *J Cell Physiol*. **209**(2), 428-438.
- Morgan, D.O. (1995). Principles of CDK regulation. *Nature*. **374**, 131-134.
- Ohtsubo, M. and Roberts, J.M. (1993). Cyclin-dependent regulation of G1 in mammalian fibroblasts. *Science* **259**, 1908-1912.
- Ouadid-Ahidouch, H., Roudbaraki, M., Ahidouch, A., Delcourt, P. and Prevarskaya, N. (2004). Cell-cycle-dependent expression of the large Ca^{2+} -activated K^+ channels in breast cancer cells. *Biochem Biophys Res Commun*. **316**(1), 244-251.
- Parihar, A.S., Coghlan, M.J., Gopalakrishnan, M. and Shieh, C.C. (2003). Effects of intermediate-conductance Ca^{2+} -activated K^+ channel modulators on human prostate cancer cell proliferation. *Eur J Pharmacol*. **471**(3), 157-164.
- Takahashi, H., Abe, M., Sugawara, T., Tanaka, K., Saito, Y., Fujimura, S., Shibuya, M. and Sato, Y. (1998). Clotrimazole, an imidazole antimycotic, is a potent inhibitor of angiogenesis. *Jpn J Cancer Res*. **89**, 445-451.
- Toyoshima, H. and Hunter, T. (1994). p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. *Cell*. **78**, 67-74.
- Yoshida, Y. and Aoyama, Y. (1987). Interaction of azole antifungal agents with cytochrome P-45014DM purified from *Saccharomyces cerevisiae* microsomes. *Biochem Pharmacol*. **36**, 229-235.